Skye Bioscience, Inc. (SKYE): Capital Expenditures
$6.3K
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
-39.2%
3-year compound annual growth
-2.7%
5-year compound annual growth
+12.3%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.3K | -99.6% | 2026-03-10, From 2025-01-01 |
| 2024-12-31 | $1.60M | n/m | 2026-03-10, From 2024-01-01 |
| 2023-12-31 | $12.6K | -55.3% | 2025-03-20, From 2023-01-01 |
| 2022-12-31 | $28.1K | -69.1% | 2024-03-22, From 2022-01-01 |
| 2021-12-31 | $90.9K | n/m | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $7.2K | n/a | 2022-03-28, From 2020-01-01 |
| No annual figure between 2018-12-31 and 2020-12-31. | |||
| 2018-12-31 | $4.4K | -77.7% | 2020-03-23, From 2018-01-01 |
| 2017-12-31 | $19.7K | +76.8% | 2019-03-14, From 2017-01-01 |
| 2016-12-31 | $11.1K | +460.9% | 2018-03-19, From 2016-01-01 |
| 2015-12-31 | $2.0K | -91.5% | 2017-03-10, From 2015-01-01 |
| 2014-12-31 | $23.3K | n/a | 2016-03-21, From 2014-01-01 |
| No annual figure between 2013-10-31 and 2014-12-31. | |||
| 2013-10-31 | $49.1K | n/a | 2014-01-27, From 2012-11-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Skye Bioscience, Inc. (SKYE) | 2025-12-31 | $6.3K | -99.6% |
| Biofrontera Inc. (BFRI) | 2025-12-31 | $2.0K | -80.0% |
| TuHURA Biosciences, Inc. (HURA) | 2025-12-31 | $76.1K | +31.4% |
| Talphera, Inc. (TLPH) | 2024-12-31 | $0 | -100.0% |
| Veru Inc. (VERU) | 2025-09-30 | $1.1K | -99.3% |
| Sol-Gel Technologies Ltd. (SLGL) | 2025-12-31 | $47.0K | n/m |
| Sunshine Biopharma Inc. (SBFM) | 2025-12-31 | $174.5K | -89.5% |
| Yarrow Bioscience, Inc. (YARW) | 2025-12-31 | $0 | -100.0% |
| PDS Biotechnology Corp (PDSB) | 2025-12-31 | $0 | -100.0% |
Compare SKYE, BFRI, HURA, TLPH side by side · Screen every company in Pharmaceutical Preparations ↗